RxDoctor Payments Data

Fabio Piazza, MD

Family Medicine · Hasbrouck Heights, NJNPI 1023226958

Payments from drug & device makers

$1,437in general payments, 2019–2025

Across 77 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$337
  • Lilly USA, LLC$319
  • Intra-sana Laboratories$146
  • Nevro Corp.$121
  • Pfizer$103
  • Amgen$87
  • plus $323 from 15 others

What the payments were for

  • Food & beverage$1,437100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,437 in reported general payments places this provider in the 70th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$88,448
Medicare patients
221
Services billed
865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin49$51,483
JanuviaSitagliptin Phosphate39$40,438
OzempicSemaglutide23$39,839
EliquisApixaban34$39,094
XareltoRivaroxaban20$26,710
JanumetSitagliptin Phos/Metformin Hcl25$15,171
ValiumDiazepam11$14,274
FarxigaDapagliflozin Propanediol13$11,294
VascepaIcosapent Ethyl25$10,055
MyrbetriqMirabegron12$9,239
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,960
Breo ElliptaFluticasone/Vilanterol11$5,160
Atorvastatin Calcium319$4,330
Rosuvastatin Calcium171$2,804
Olmesartan Medoxomil36$2,758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$12$55,61064 claims
Boehringer IngelheimJardiance$47$51,48349 claims
Novo NordiskOzempic$337$39,83923 claims
PfizerEliquis$103$39,09434 claims
GSKTrelegy Ellipta, Breo Ellipta$13$14,12025 claims
AstraZenecaFarxiga$58$11,29413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Hasbrouck Heights

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →